RU2006123312A - Фармацевтические композиции - Google Patents
Фармацевтические композиции Download PDFInfo
- Publication number
- RU2006123312A RU2006123312A RU2006123312/15A RU2006123312A RU2006123312A RU 2006123312 A RU2006123312 A RU 2006123312A RU 2006123312/15 A RU2006123312/15 A RU 2006123312/15A RU 2006123312 A RU2006123312 A RU 2006123312A RU 2006123312 A RU2006123312 A RU 2006123312A
- Authority
- RU
- Russia
- Prior art keywords
- arthritis
- rheumatoid arthritis
- mtor inhibitor
- medicament
- activity against
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 10
- 206010003246 arthritis Diseases 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 9
- 229940124302 mTOR inhibitor Drugs 0.000 claims 8
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 8
- 239000003795 chemical substances by application Substances 0.000 claims 7
- 230000000694 effects Effects 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 210000002950 fibroblast Anatomy 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 210000002540 macrophage Anatomy 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000035755 proliferation Effects 0.000 claims 2
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
- 241001111421 Pannus Species 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 229960002930 sirolimus Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0327840.5 | 2003-12-01 | ||
| GBGB0327840.5A GB0327840D0 (en) | 2003-12-01 | 2003-12-01 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2006123312A true RU2006123312A (ru) | 2008-01-20 |
Family
ID=29798110
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006123312/15A RU2006123312A (ru) | 2003-12-01 | 2004-11-30 | Фармацевтические композиции |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20070117833A1 (https=) |
| EP (1) | EP1819361A2 (https=) |
| JP (1) | JP2007512381A (https=) |
| KR (1) | KR20060122877A (https=) |
| CN (1) | CN1886157A (https=) |
| AU (1) | AU2004294282B2 (https=) |
| BR (1) | BRPI0417146A (https=) |
| CA (1) | CA2546738A1 (https=) |
| GB (1) | GB0327840D0 (https=) |
| RU (1) | RU2006123312A (https=) |
| WO (1) | WO2005053661A2 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1478648E (pt) | 2002-02-01 | 2014-07-15 | Ariad Pharma Inc | Compostos contendo fósforo e suas utilizações |
| WO2006053754A1 (en) * | 2004-11-19 | 2006-05-26 | Novartis Ag | COMBINATIONS OF ANTI-ATHEROSCLEROTIC PEPTIDES AND AN mTOR INHIBITING AGENT AND THEIR METHODS OF USE |
| WO2007059106A2 (en) * | 2005-11-14 | 2007-05-24 | Ariad Gene Therapeutics, Inc. | Administration of mntor inhibitor to treat patients with cancer |
| EP1880723A1 (en) * | 2006-07-14 | 2008-01-23 | Novartis AG | Combination of mTOR inhibitor and antifolate compound |
| WO2007080124A1 (en) * | 2006-01-12 | 2007-07-19 | Novartis Ag | Combination of mtor inhibitor and antipolate compound |
| KR20080090493A (ko) * | 2006-02-02 | 2008-10-08 | 노파르티스 아게 | 결절성 경화증의 치료 |
| US20090023768A1 (en) * | 2006-02-24 | 2009-01-22 | Novartis Ag | Rapamycin derivatives for treating neuroblastoma |
| JP2010509400A (ja) | 2006-11-14 | 2010-03-25 | アリアド・ファーマシューティカルズ・インコーポレイテッド | 経口処方組成物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9221220D0 (en) * | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
| US5258389A (en) * | 1992-11-09 | 1993-11-02 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives |
| US5985890A (en) * | 1995-06-09 | 1999-11-16 | Novartis Ag | Rapamycin derivatives |
| GB0123025D0 (en) * | 2001-09-25 | 2001-11-14 | Eirx Therapeutics Ltd | Apoptosis |
| BR0306858A (pt) * | 2002-01-10 | 2004-11-03 | Novartis Ag | Sistemas de liberação de drogas para a prevenção e tratamento de doenças vasculares compreendendo rapamicina e derivados da mesma |
| PT1478648E (pt) * | 2002-02-01 | 2014-07-15 | Ariad Pharma Inc | Compostos contendo fósforo e suas utilizações |
| WO2003106622A2 (en) * | 2002-05-30 | 2003-12-24 | The Children's Hospital Of Philadelphia | Methods for treatment of acute lymphocytic leukemia |
| TW200509958A (en) * | 2003-02-14 | 2005-03-16 | Combinatorx Inc | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines |
-
2003
- 2003-12-01 GB GBGB0327840.5A patent/GB0327840D0/en not_active Ceased
-
2004
- 2004-11-30 RU RU2006123312/15A patent/RU2006123312A/ru not_active Application Discontinuation
- 2004-11-30 CN CNA2004800355130A patent/CN1886157A/zh active Pending
- 2004-11-30 CA CA002546738A patent/CA2546738A1/en not_active Abandoned
- 2004-11-30 US US10/581,069 patent/US20070117833A1/en not_active Abandoned
- 2004-11-30 AU AU2004294282A patent/AU2004294282B2/en not_active Expired - Fee Related
- 2004-11-30 KR KR1020067010547A patent/KR20060122877A/ko not_active Withdrawn
- 2004-11-30 BR BRPI0417146-2A patent/BRPI0417146A/pt not_active IP Right Cessation
- 2004-11-30 WO PCT/EP2004/013587 patent/WO2005053661A2/en not_active Ceased
- 2004-11-30 EP EP04803369A patent/EP1819361A2/en not_active Withdrawn
- 2004-11-30 JP JP2006541869A patent/JP2007512381A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2007512381A (ja) | 2007-05-17 |
| CA2546738A1 (en) | 2005-06-16 |
| WO2005053661A3 (en) | 2005-12-29 |
| AU2004294282B2 (en) | 2009-05-07 |
| KR20060122877A (ko) | 2006-11-30 |
| AU2004294282A1 (en) | 2005-06-16 |
| WO2005053661A2 (en) | 2005-06-16 |
| GB0327840D0 (en) | 2003-12-31 |
| US20070117833A1 (en) | 2007-05-24 |
| CN1886157A (zh) | 2006-12-27 |
| BRPI0417146A (pt) | 2007-03-06 |
| EP1819361A2 (en) | 2007-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2005063297A3 (en) | Melatonin combination therapy for improving sleep quality | |
| EP1426375A3 (en) | Analgesic spiroindole derivatives | |
| SI1154993T1 (en) | Thioamide derivatives | |
| WO2003068171A3 (en) | Method and composition for treatment of inflammation and aids-associated neurological disorders | |
| WO2005047244A3 (en) | Inhibition of fgfr3 and treatment of multiple myeloma | |
| CA2532565A1 (en) | Use of calcitonin in osteoarthritis | |
| EP1769797A3 (en) | Methods and compositions using cetirizine in combination with leukotriene inhibitors for treating conditions responsive to leukotriene inhibition | |
| RU2006123312A (ru) | Фармацевтические композиции | |
| WO2004039325A3 (en) | Treatment of pain with jnk inhibitors | |
| CA2148194A1 (en) | Cyclopeptides of the formula i | |
| RU2004135563A (ru) | Лекарственное средство для лечения повышенной активности мочевого пузыря | |
| PL368971A1 (en) | Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate | |
| CA2274686A1 (en) | Sulfonic acid or sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds | |
| EP1086099A4 (en) | COMPOUNDS BASED ON SULFONIC ACID OR SULFONYLAMINO N- (HETEROARALKYL) -AZAHETEROCYCLYLAMIDE | |
| EP2138175A3 (en) | Formulations comprising valsartan for treating diabetes or microalbuminuria | |
| CA2476939A1 (en) | Pharmaceutical combinations of cox-2 inhibitors and opiates | |
| WO2002065989A3 (en) | Aminoglycoside treatment for lysosomal storage diseases | |
| IL145269A0 (en) | Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent mood disorders, adjustment disorders or mixed anxiety-depression disorders | |
| WO2001005408A8 (en) | Fat-binding polymers, optionally combined with lipase inhibitors | |
| Santos et al. | Multimodal analgesia for postoperative pain in Asia: a review of evidence with clinical focus on dexketoprofen and tramadol/dexketoprofen fixed-dose combination. | |
| PT1244438E (pt) | Utilizacao de antagonistas dos receptores beta-adrenergicos para o fabrico de um medicamento destinado ao tratamento de perturbacoes da retina externa | |
| JP2007512381A5 (https=) | ||
| Budacu et al. | e al., Glucocoricoids and postoperative disease in oralmaxillofacial surgery | |
| CA2518205A1 (en) | Use of a fibrate and orlistat for the treatment of obesity | |
| US5081129A (en) | Method of treatment of anemia with seratonin antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20090629 |